1. Data & Insights

The AI Advantage: When and Where to Apply It in Your Patient Support Program

Written by Posted on Less than 0 min read

Today’s guest post comes from William Grambley, Chief Product Officer at AssistRx.

 

William discusses four specific uses cases for how AI can create efficiencies and improve patient support programs for both healthcare providers and patients. He provides three considerations that life sciences organizations should evaluate when adopting AI in their patient support programs.

 

To learn more:

Read on for William’s insights.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 28
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

As MFP Approaches, Transparency Is More Important Than Ever

Today’s guest post comes from Angie Franks, Chief Executive Officer of Kalderos. Angie discusses how the Maximum Fair Price provision of the Inflation Reduction Act of 2022 will challenge providers, pharmacies, and manufacturers. She explains how Kalderos’ Truzo platform could reduce duplicate claims and address compliance issues. To learn more, register for Kalderos’ October 25 […]
2 min read
0
  1. Department: HBC

NOW AVAILABLE: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

I am pleased to announce that Drug Channels Institute’s new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Download a free 30-page report overview—including key industry trends, What’s New in this edition, the Table of Contents, and a List of Exhibits Read the press release: […]
4 min read
0
  1. Media & Marketing

Drug Channels News Roundup, June 2024: Cordavis Humira Update, OptumRx’s New Biosim Biz, Generic Drugs’ Wild Ride, IRA Predictions, and Dr. G on Med School

Happy 248th birthday, America! Before you launch your July 4 festivities, Drug Channels offers some fireworks of its own: CVS Health’s Cordavis is winning the Humira biosimilar battle Meet NUVAILA, OptumRx’s new biosimilar procurement business The acquisition cost revolution hits a speedbump following NADAC volatility Five predictions about the IRA’s impact on the drug channel […]
2 min read
0
  1. Corporate Strategy

Inside the 2025 PSAO Market: How Wholesalers Shape Pharmacy–PBM Relationships

Pharmacy services administrative organizations (PSAOs), which operate between pharmacy benefit managers (PBMs) and smaller pharmacies, are among the most mysterious—and misunderstood—intermediaries in our complex U.S. drug channel. Adding to the mystery: the largest PSAOs are owned by the three multi-billion dollar, public companies that also dominate pharmaceutical distribution—Cencora, Cardinal Health, and McKesson. These companies sit […]
2 min read
0
  1. Corporate Strategy

Compliance is Futile Without Transparency: 340B, MDRP, MFP Overlap Lead to Iceberg Ahead

Today’s guest post comes from Angie Franks, CEO at Kalderos Angie describes the compliance challenges that stakeholders face in managing the complex interactions of the 340B Drug Pricing Program, the Medicaid Drug Rebate Program, and IRA’s Maximum Fair Price and inflation rebate provisions. She explains how clean, comprehensive claims data can resolve these issues. To learn […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, September 2025: Mark Cuban Wins (Again), Biosimilar Pricing Double Standards, Part D Collapse, Fresh 340B Facts, and The Pitt

Autumn is here! Curl up with your Labubu’s favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch: Mark Cuban’s company trims third-party fat but insured patients sometimes pay more Express Scripts boots Stelara, but clings to its biosimilar pricing double standard Thanks, IRA! The Part D market keeps unravelling Fresh […]
2 min read
0
  1. Holiday & Events

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

Eeek! It’s time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats: Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy Vampiric! Prior authorization sinks its fangs into providers’ time Wicked! How the IRA will put a stake through […]
2 min read
0
  1. Data & Insights

The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. I’ll be joined by special guest Antonio Ciaccia, CEO of 46brooklyn Research, and President of 3 Axis Advisors. Click here to see the original post from March 2025. Next week, Drug […]
3 min read
0
  1. Trends & External Forces

HCP Perspectives: Access Challenges in Treating Diabetes & Obesity

Today’s guest post is from Dr. Preeti Parikh, a practicing pediatrician and VP, Executive Medical Director at GoodRx. At the recent Publicis Health Media HealthFront event, Preeti hosted a dialogue on the main stage with Dr. Minisha Sood. They discussed new GoodRx research and had a candid discussion about their daily challenges in caring for […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, July 2024: My $0.02 on FTC’s PBM Report, GoodRx & Humira, Averon = CVS + Cardinal, IRA vs. 340B, and My Favorite Chart

Bello! The hot and hazy days of summer are here. Go for a swim to cool off and then enjoy this refreshing selection of articles chosen by Drug Channels para tu. Did the FTC’s compelling interim report prove its case? GoodRx joins the Humira biosimilar price war with Boehringer Ingelheim Averon revealed to be a […]
2 min read
0
  1. Media & Marketing

How Large PBMs Make Money Today: A 2025 Drug Channels Update

During my PBM Industry Update: Trends, Challenges, and What’s Ahead video webinar, I explored the latest trends, emerging data, and strategic shifts transforming the pharmacy benefit management (PBM) industry. In the video clip below, I explain how PBM compensation models continue to evolve: Traditional profit sources, such as mail dispensing of nonspecialty drugs and retained […]
2 min read
0
  1. Media & Marketing

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low

Is the gross-to-net bubble—the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and discounts—finally beginning to deflate? Drug Channels Institute (DCI) estimates that the gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the previous year. Yet despite this record total, the […]
2 min read
0
  1. Department: HBC

Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner

Today’s guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy. Richard outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services […]
2 min read
0
  1. Department: HBC

Pharmacy Shakeout: Why U.S. Drugstores Are Disappearing

During my recent video webinar—What’s Next for Retail Pharmacy: Data, Debate, and Disruption—Antonio Ciaccia of 46brooklyn Research joined me to explore the data, trends, and strategic shifts driving a major shakeout in the retail pharmacy sector. In the short video excerpt below, I break down five key economic forces putting intense pressure on U.S. drugstores. […]
2 min read
0
  1. Data & Insights

The AI Advantage: Evolving Patient Engagement Strategies to Improve Outcomes

Today’s guest post comes from Stacey Little, Chief Growth Officer at AssistRx. In this guest post, Stacey explores how artificial intelligence (AI) is helping life sciences organizations move beyond fragmented support models to deliver more integrated and personalized patient engagement. She outlines three distinct approaches to structuring patient support programs and discusses how AI-driven tools—such […]
2 min read
0
  1. Data & Insights

PBM Industry Update: Trends, Challenges, and What’s Ahead (NEW Live Video Webinar)

Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. to 1:30 p.m. ET This page […]
5 min read
0
  1. Trends & External Forces

Why the IRA Will Encourage Part D Plans to Prefer High-List, High-Rebate Drugs (video)

In my recent Drug Channel Implications of the Inflation Reduction Act video webinar, I explained the intended and unintended consequences of the Inflation Reduction Act of 2022 (IRA) for the commercial market and drug channel participants. In the video excerpt below, I walk through a mathematical example to show why the IRA will encourage Part […]
2 min read
0
  1. Corporate Strategy

Drug Channels Leadership Forum: Request an Invitation Before It’s Too Late!

The inaugural Drug Channels Leadership Forum (DCLF) is coming soon! This exclusive event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Our first event will provide attendees with an opportunity to explore the most pressing strategic issues and crucial uncertainties that will impact all participants across […]
3 min read
0
  1. Media & Marketing

Drug Channels Leadership Forum: Full Agenda Now Available (Spoiler: It’s Awesome!)

I am pleased to announce the full agenda for the inaugural Drug Channels Leadership Forum, which will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Everyone here at Drug Channels Institute (DCI) is excited to bring this novel event to the drug channels community. I personally assembled […]
3 min read
0
  1. Channel: Drug

Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies

Two weeks ago, Senator Bill Cassidy—now chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP)—dropped a must-read, eyebrow-raising report on the out-of-control 340B Drug Pricing Program. (Link below.) The report reveals previously confidential information showing how billions are funneled to health systems and pharmacies—with manufacturers unable to follow the flow. Below, we […]
2 min read
0
Next